United Guardian develops and manufactures specialty chemical products for cosmetic, pharmaceutical, and medical applications. The company's core offering is LUBRAJEL, a proprietary hydrogel platform used as a multifunctional ingredient in personal care formulations, medical devices, and pharmaceutical preparations. Related products include B-122, a powdered lubricant for pressed cosmetics and industrial use, and LUBRASIL II SB, a silicone-enhanced variant. The company also markets ORCHID COMPLEX, an oil-based botanical extract for cosmetic applications.
The pharmaceutical segment includes RENACIDIN, a prescription product for catheter calcification management, and CLORPACTIN WCS-90, a chlorine-based topical antimicrobial used primarily in urology. Medical applications for Lubrajel formulations span catheter lubrication, medical device coating, condom lubrication, and oral care products. The company's sexual wellness segment offers hydrogel-based ingredient lines marketed under the Natrajel brand, designed to provide lubrication, moisturization, and sensory properties.
United Guardian operates as a small-scale manufacturer with 24 full-time employees and is headquartered in Hauppauge, New York. The company distributes products domestically and internationally, serving cosmetic manufacturers, pharmaceutical companies, medical device makers, and consumer wellness brands as ingredient suppliers and direct manufacturers.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | — | $0.71 | +26.8% | |
| 2023 | — | $0.56 | +0.0% | |
| 2022 | — | $0.56 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-21 | 0001171843-25-001611 | SEC ↗ |
| 2023-12-31 | 2024-03-22 | 0001171843-24-001526 | SEC ↗ |
| 2022-12-31 | 2023-03-23 | 0001171843-23-001846 | SEC ↗ |
| 2021-12-31 | 2022-03-23 | 0001171843-22-002061 | SEC ↗ |
| 2020-12-31 | 2021-03-22 | 0001171843-21-001963 | SEC ↗ |
| 2019-12-31 | 2020-03-26 | 0001171843-20-002021 | SEC ↗ |
| 2018-12-31 | 2019-03-21 | 0001171843-19-001878 | SEC ↗ |
| 2017-12-31 | 2018-03-22 | 0001171843-18-002183 | SEC ↗ |
| 2016-12-31 | 2017-03-23 | 0001171843-17-001709 | SEC ↗ |
| 2015-12-31 | 2016-03-24 | 0001171843-16-008781 | SEC ↗ |
| 2014-12-31 | 2015-03-26 | 0001171843-15-001673 | SEC ↗ |
| 2013-12-31 | 2014-03-24 | 0001171843-14-001385 | SEC ↗ |
| 2012-12-31 | 2013-03-21 | 0001171843-13-001097 | SEC ↗ |
| 2011-12-31 | 2012-03-26 | 0001171843-12-001021 | SEC ↗ |
| 2010-12-31 | 2011-03-25 | 0001171843-11-000851 | SEC ↗ |
| 2009-12-31 | 2010-03-25 | 0001171843-10-000469 | SEC ↗ |
| 2008-12-31 | 2009-03-24 | 0001171843-09-000269 | SEC ↗ |
| 2007-12-31 | 2008-03-27 | 0000101295-08-000004 | SEC ↗ |